Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMD0I29)

Drug Name

ATL-104 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 2	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Discontinued Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Receptor unspecific (Rec)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Prosaptide TX14(A)	DME25TI	Neuropathic pain	8E43.0	Phase 2	[3]
Lactermin	DM8ANIM	Oral mucositis	DA01.11	Phase 1	[4]
BT-063	DMS4H30	Autoimmune diabetes	5A10	Phase 1	[5]
PV-707	DMRODZS	Skin burns	ME65.0	Discontinued in Phase 2	[6]
YP-004	DMK1UJM	Solid tumour/cancer	2A00-2F9Z	Terminated	[7]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	ClinicalTrials.gov (NCT00163280) Safety, Tolerability and Efficacy of ATL-104 in Oral Mucositis. U.S. National Institutes of Health.
2	Treatment of oral mucositis after peripheral blood SCT with ATL-104 mouthwash: results from a randomized, double-blind, placebo-controlled trial. Bone Marrow Transplant. 2009 Apr;43(7):563-9.
3	Central action of prosaptide TX14(A) against gp120-induced allodynia in rats. European Journal of Pain Volume 12, Issue 1, January 2008, Pages 76-81.
4	Mammalian lactoferrin receptors: structure and function. Cell Mol Life Sci. 2005 Nov;62(22):2560-75.
5	Clinical pipeline report, company report or official report of Biotest.
6	EP patent application no. 1904089, Promotion of epithelial regeneration.
7	CA patent application no. 815512, Method for increasing the efficiency of double-strand break-induced mutagenesis.